source
- AstraZeneca's breast cancer pill camizestrant fails to improve progression-free survival in pivotal SERENA-4 trialAstraZeneca announced that its oral estrogen receptor degrader camizestrant, marketed as Etcamah, did not meet its primary endpoint in the phase III SERENA-4 trial. The study evaluated camizestran…
- Setbacks for Novartis; Anthropic looks for a dealmaker; and moreWelcome back to another edition of Endpoints Weekly! While it is still technically summer, the season is starting to turn now that we’re past Labor Day. It will be a sprint to Thanksgiving, and we’…Endpoints · 6m ago↗ source